Please login to the form below

Not currently logged in
Email:
Password:

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201

Dispute covers multiple drugs in Daiichi's antibody-drug conjugates pipeline

Daiichi-Sankyo

A partnership between Seattle Genetics and Japan’s Daiichi Sankyo on antibody-drug conjugates, which ended in 2015, has sparked a lawsuit between the two companies.

The dispute covers multiple drugs in Daiichi’s ADC pipeline, including DS-8201 (trastuzumab deruxtecan), a HER2-targeting drug for breast cancer licensed by AstraZeneca for $1.35bn upfront earlier this year.

Seattle and Daiichi worked on ADC drugs for various solid tumour indications between 2008 and 2015, with the Japanese company paying $4m upfront in the deal. At the time, it was reported that the alliance involved Daiichi licensing a technology used to link cell-killing compounds to the antibody component of ADCs.

Daiichi said today that Seattle Genetics is “claiming certain intellectual property rights related to Daiichi Sankyo’s ADC products”, a stance which it insists is “without merit”.

The original agreement between the companies cover ADCs which are “distinct from ADC products currently being developed in the Daiichi Sankyo pipeline,” it claims. There’s no word yet on whether this will have any bearing on its deal with AZ, which is worth up to $6.9bn.

Seattle meanwhile asserts that the linker technology being used in Daiichi’s ADCs – including DS-8201 – is covered by the earlier agreement.

“The linker and other ADC technology used in these drug candidates are improvements to Seattle Genetics’ pioneering ADC technology, the ownership of which are automatically assigned to Seattle Genetics under the terms of the agreement,” it said in its own statement on the legal dispute.

Seattle suggests the two parties have been trying to resolve the dispute out of the courts, but that Daiichi has now decided on litigation to bring the matter to a conclusion.

DS-8201 has been granted a priority review from the FDA, setting up a potential approval in the second quarter of 2022, and has been tipped by analysts to become a $2bn product in 2024, with additional upside if Daiichi and AZ can expand its use into tumours that express lower levels of the HER2 biomarker than would ordinarily warrant HER2-targeted drugs.

ADCs feature prominently in Daiichi’s oncology pipeline, with additional candidates in early stage testing for breast cancer, non-small cell lung cancer (NSCLC) and other solid tumours, including anti-HER3 ADC U3-1402, TROP2-targeting DS-1062 and DS-7300, which targets B7-H3 and started a phase 1/2 trial last month.

Article by
Phil Taylor

5th November 2019

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics